Question 1

Does Los Angeles Capital Management own SYRE stock?

Accepted Answer

Yes. As of its Q2 2026 13F, Los Angeles Capital Management holds 2,310 shares of SYRE (Spyre Therapeutics), worth $205,082.

Question 2

How many shares of SYRE does Los Angeles Capital Management own?

Accepted Answer

As of its Q2 2026 13F, Los Angeles Capital Management holds 2,310 shares of SYRE (Spyre Therapeutics).

Question 3

What is Los Angeles Capital Management's SYRE position worth?

Accepted Answer

As of its Q2 2026 13F, Los Angeles Capital Management's SYRE position is worth $205,082.

Question 4

Is Los Angeles Capital Management buying or selling SYRE?

Accepted Answer

In Q2 2026, Los Angeles Capital Management reduced its SYRE position by 3,548 shares (-60.6%).

Question 5

When did Los Angeles Capital Management first buy SYRE?

Accepted Answer

Los Angeles Capital Management first reported SYRE in its Q3 2025 13F and has listed it in 4 quarterly 13F filings.

Quarter	Action	Shares	Change	Value	Weight	Price	Conviction
2026-Q2 Latest	Decreased	2,310	-60.6%	$205,082	0.0%	$88.78	0
2026-Q1	Decreased	5,858	-54.5%	$295,477	0.0%	$50.44	0
2025-Q4	Decreased	12,882	-29.1%	$312,519	0.0%	$32.76	0
2025-Q3	New	18,172	—	$304,563	0.0%	$16.76	32